Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Browsing Category
HHS-OIG
HHS OIG: Listing of Pharmaceutical and Device Corporate Integrity…
Below is a list in alphabetic order of the major pharmaceutical and medical device manufacturer corporate integrity agreements…
Amgen Settlement and Corporate Integrity Agreement
Adding to the long list of pharmaceutical settlements involving off-label promotion, Amgen Inc., the world’s largest biotechnology…
HHS OIG Solicits Input on Safe Harbor Provisions
The Office of the Inspector General (OIG) for the Department of Health and Human Services (HHS) recently released a Notice in the…
2012 HHS OIG Semiannual Report to Congress
The Office of Inspector General (OIG) for the Department of Health and Human Services (HHS) recently released its Semiannual…
United States v. Caronia: A Victory for Free Speech vs. Off Label Promotion
The United States Court of Appeals for the Second Circuit (New York), in a 2-1 opinion, vacated the criminal conviction of a…
HHS Office of Inspector General: Top Management and Performance Challenges…
Annually, the Office of Inspector General (OIG) prepares a summary of the most significant management and performance challenges…
HHS and Attorney General Concerned with Upcoding
Over the last three years, the Health Care Fraud Prevention and Enforcement Action Team (HEAT) has recovered over $10.2 billion in…
HHS OIG Summary of 2nd 2012 Roundtable on Corporate Integrity Agreements
The Office of the Inspector General (OIG) for the Department of Health and Human Services (HHS) recently released the summary of a…
HHS OIG Work Plan for Fiscal Year 2013
The U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) recently released its Work Plan for…
HHS and Private Payers Announce Partnership to Prevent Healthcare Fraud
Department of Health and Human Services (HHS) Secretary Kathleen Sebelius and Attorney General Eric Holder announced the launch of…